Science 37 leverages innovative technologies to transform the landscape of clinical research through its proprietary Metasite™ platform. This platform enables decentralized clinical trials, allowing patients to participate from their homes or local healthcare providers, thereby expanding access to a more diverse patient population. The Metasite™ integrates various functionalities, including electronic consent (eConsent), patient-reported outcomes (ePRO), telemedicine, and the use of connected devices, all within a unified system that streamlines the workflow for both patients and study staff. This approach not only enhances patient engagement and retention but also ensures compliance with Good Clinical Practice (GCP) standards, resulting in high-quality data collection.

In addition to its technological capabilities, Science 37 emphasizes the importance of in-house clinical expertise across multiple therapeutic areas, including oncology, infectious diseases, and central nervous system disorders. The company employs a team of experienced telemedicine investigators and mobile nurses, ensuring that patients receive comprehensive support throughout their trial journey. By combining advanced technology with expert clinical oversight, Science 37 aims to deliver a patient-centric research experience that accelerates trial timelines and improves overall study performance, ultimately making clinical research more accessible and effective for everyone involved.

United States

Science 37's mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration.

Science 37

Company Details